In a phase II open-label study ledipasvir, sofosbuvir and ribavirin were used to treat HCV-infected patients who have advanced liver disease and who had or had not undergone liver transplantation. Patients (n = 337) with either HCV genotype 1 (99%) or genotype 4 (1%) were treated for either 12 or 24 weeks. Sustained virologic response (SVR) was assessed 12 weeks after treatment. SVR12 was reached in 86–89% of those who were not transplant recipients. SVR12 ranged from 60–96% in transplant recipients depending on the severity of liver disease. Owing to adverse events, 13 (4%) patients discontinued treatment.
References
Charlton, M. et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 10.1053/j.gastro.2015.05.010
Rights and permissions
About this article
Cite this article
Treatment of HCV infection in advanced liver disease. Nat Rev Gastroenterol Hepatol 12, 370 (2015). https://doi.org/10.1038/nrgastro.2015.101
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.101